Top-ten medicines by Product Sales: Tagrisso: $784M (+86%); Lynparza: $283M (+89%); Symbicort: $585M (-13%); Nexium: $393M (-11%); Brilinta: $389M (+23%); Farxiga: $377M (+11%); Pulmicort: $333M (+16%); Crestor: $310M (-8%); Imfinzi: $338M; Faslodex: $267M (+8%).
Net Income: $107M (-66.5%); EPS: $0.10 (-63.0%); Non-GAAP EPS: $0.73 (-27.0%); CF Ops: $491M (-754.7%).
2019 Guidance: Product Sales: An increase by a low double-digit percentage from a high single-digit percentage increase; Core EPS: $3.50 – 3.70 (unch).
Shares are up 5% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.